# Clinical Study Protocol: Motile Cilia-CSF Flow in Idiopathic Scoliosis

## Protocol Title
"Evaluation of Cerebrospinal Fluid Flow Dynamics and Motile Cilia Function in Adolescent Idiopathic Scoliosis: A Translational Biomarker Study"

## Protocol Version
Version 2.0 - December 2024

## Principal Investigator
[PI Name], MD, PhD
Department of [Department]
[Institution]

## Study Objectives

### Primary Objective
To evaluate cerebrospinal fluid (CSF) flow dynamics and motile cilia function as biomarkers for idiopathic scoliosis (IS) progression in adolescents.

### Secondary Objectives
1. To correlate CSF flow abnormalities with curve progression rates
2. To assess nasal epithelial cilia function as a surrogate for ependymal cilia
3. To evaluate genetic variants in motile cilia genes in IS patients
4. To establish normative CSF flow parameters in healthy adolescents

## Study Design

### Study Type
Prospective, longitudinal, observational study with case-control design

### Study Population
- **Cases**: Adolescents (9-16 years) with idiopathic scoliosis
- **Controls**: Age- and sex-matched healthy adolescents
- **Total Sample Size**: 200 participants (100 cases, 100 controls)

### Study Duration
- **Recruitment Period**: 24 months
- **Follow-up Period**: 18 months per participant
- **Total Study Duration**: 42 months

## Inclusion and Exclusion Criteria

### Inclusion Criteria - Cases
1. Age 9-16 years at enrollment
2. Diagnosis of idiopathic scoliosis confirmed by:
   - Cobb angle ≥10° on standing radiographs
   - Absence of congenital vertebral anomalies
   - No neuromuscular or syndromic scoliosis
3. Tanner stage 1-4 (pre-pubertal to mid-pubertal)
4. Ability to undergo MRI without sedation
5. Informed consent from parent/guardian and assent from participant

### Inclusion Criteria - Controls
1. Age 9-16 years at enrollment
2. No history of spinal deformity or back pain
3. Normal physical examination of spine
4. Tanner stage 1-4
5. Ability to undergo MRI without sedation
6. Informed consent from parent/guardian and assent from participant

### Exclusion Criteria (Both Groups)
1. Contraindications to MRI (metal implants, claustrophobia)
2. Pregnancy or breastfeeding
3. Active infection or fever
4. Prior spinal surgery
5. Neurological conditions affecting CSF flow
6. Inability to comply with study procedures

## Study Procedures

### Visit Schedule
- **Baseline Visit**: Comprehensive assessment
- **Follow-up Visits**: Every 6 months for 18 months
- **Total Visits**: 4 per participant

### Baseline Visit Procedures

#### 1. Clinical Assessment
- **Demographics**: Age, sex, race/ethnicity
- **Anthropometrics**: Height, weight, BMI
- **Tanner Staging**: Pubertal development assessment
- **Spinal Examination**: Adam's forward bend test, scoliometer measurement
- **Medical History**: Birth history, developmental milestones, family history

#### 2. Imaging Studies
- **Standing Radiographs**: Full spine AP and lateral views
- **Phase-Contrast MRI**: CSF flow quantification
  - Aqueduct of Sylvius flow measurement
  - Fourth ventricle flow rates
  - Cervical spinal canal flow mapping
- **Cine-MRI**: Craniocervical junction dynamics

#### 3. Biospecimen Collection
- **Serum**: 10mL for biomarker analysis
- **Nasal Epithelial Brushings**: Cilia beat frequency analysis
- **Optional CSF**: When clinically indicated (e.g., diagnostic lumbar puncture)

#### 4. Genetic Testing
- **Targeted Sequencing**: Motile cilia genes (PTK7, DYX1C1, CCDC40, CCDC151, C21ORF59)
- **Family History**: Three-generation pedigree for genetic analysis

### Follow-up Visit Procedures

#### 1. Clinical Assessment
- **Anthropometrics**: Height, weight, BMI
- **Tanner Staging**: Pubertal development progression
- **Spinal Examination**: Curve progression assessment

#### 2. Imaging Studies
- **Standing Radiographs**: Full spine AP and lateral views
- **Phase-Contrast MRI**: CSF flow quantification (same protocol as baseline)

#### 3. Biospecimen Collection
- **Serum**: 10mL for biomarker analysis
- **Nasal Epithelial Brushings**: Cilia function assessment

## MRI Protocol Specifications

### Phase-Contrast MRI Parameters

#### Aqueduct of Sylvius Flow
- **Sequence**: 2D phase-contrast gradient echo
- **TR/TE**: 25/8 ms
- **Flip Angle**: 20°
- **Slice Thickness**: 3mm
- **Field of View**: 200×200mm
- **Matrix**: 256×256
- **Velocity Encoding**: 20 cm/s
- **Temporal Resolution**: 40ms
- **Total Acquisition Time**: 3 minutes

#### Fourth Ventricle Flow
- **Sequence**: 2D phase-contrast gradient echo
- **TR/TE**: 25/8 ms
- **Flip Angle**: 20°
- **Slice Thickness**: 4mm
- **Field of View**: 200×200mm
- **Matrix**: 256×256
- **Velocity Encoding**: 15 cm/s
- **Temporal Resolution**: 40ms
- **Total Acquisition Time**: 3 minutes

#### Cervical Spinal Canal Flow
- **Sequence**: 2D phase-contrast gradient echo
- **TR/TE**: 25/8 ms
- **Flip Angle**: 20°
- **Slice Thickness**: 5mm
- **Field of View**: 250×250mm
- **Matrix**: 256×256
- **Velocity Encoding**: 10 cm/s
- **Temporal Resolution**: 40ms
- **Total Acquisition Time**: 4 minutes

### Image Analysis Protocol

#### Flow Quantification
1. **ROI Definition**: Manual delineation of aqueduct, fourth ventricle, spinal canal
2. **Flow Calculation**: Mean velocity, peak velocity, flow volume
3. **Temporal Analysis**: Flow waveform characteristics
4. **Quality Control**: Signal-to-noise ratio, artifact assessment

#### Software Requirements
- **Analysis Platform**: MATLAB with custom scripts
- **Validation**: Phantom studies for accuracy verification
- **Reproducibility**: Inter-observer reliability testing

## Biomarker Analysis Protocol

### Serum Biomarkers

#### Ciliary Proteins
- **FOXJ1**: Transcription factor for motile cilia
- **DNAH5**: Dynein heavy chain component
- **RFX3**: Regulatory factor for cilia gene expression
- **Method**: ELISA or LC-MS/MS

#### Inflammatory Markers
- **IL-6, TNF-α**: Cytokines linked to CSF dynamics
- **CRP**: Acute phase reactant
- **Method**: Multiplex immunoassay

### Nasal Epithelial Cilia Analysis

#### High-Speed Video Microscopy
- **Equipment**: High-speed camera (≥500 fps)
- **Analysis**: Beat frequency, amplitude, coordination
- **Quality Control**: Temperature control, standardized protocols

#### Transmission Electron Microscopy
- **Sample Preparation**: Standard TEM protocols
- **Analysis**: Cilia ultrastructure, axoneme integrity
- **Quantification**: Cilia density, length, orientation

## Genetic Analysis Protocol

### Targeted Gene Panel
- **PTK7**: Protein tyrosine kinase 7
- **DYX1C1**: Dyslexia susceptibility 1 candidate gene 1
- **CCDC40**: Coiled-coil domain containing 40
- **CCDC151**: Coiled-coil domain containing 151
- **C21ORF59**: Chromosome 21 open reading frame 59

### Sequencing Method
- **Platform**: Next-generation sequencing
- **Coverage**: ≥50x average depth
- **Variant Calling**: GATK best practices
- **Annotation**: ANNOVAR or equivalent

### Analysis Pipeline
1. **Quality Control**: Read quality, coverage assessment
2. **Variant Detection**: SNVs, indels, CNVs
3. **Annotation**: Functional impact prediction
4. **Filtering**: Population frequency, pathogenicity scores
5. **Validation**: Sanger sequencing for novel variants

## Data Management

### Database Design
- **Platform**: REDCap (Research Electronic Data Capture)
- **Fields**: Demographics, clinical data, imaging results, biomarker data
- **Security**: HIPAA-compliant, encrypted data transmission
- **Backup**: Daily automated backups

### Data Collection Forms
1. **Demographics and Medical History**
2. **Clinical Assessment**
3. **Imaging Results**
4. **Biomarker Results**
5. **Genetic Analysis Results**
6. **Adverse Events**

### Quality Control
- **Data Validation**: Range checks, consistency checks
- **Missing Data**: Standardized handling procedures
- **Audit Trail**: Complete data modification history

## Statistical Analysis Plan

### Sample Size Calculation
- **Primary Endpoint**: CSF flow velocity difference between groups
- **Effect Size**: 0.5 (medium effect)
- **Power**: 80%
- **Alpha**: 0.05
- **Sample Size**: 100 per group (total 200)

### Primary Analysis
- **Primary Endpoint**: Mean CSF flow velocity in aqueduct
- **Statistical Test**: Two-sample t-test
- **Effect Size**: Cohen's d
- **Confidence Interval**: 95%

### Secondary Analyses
1. **Correlation Analysis**: CSF flow vs. curve progression
2. **Longitudinal Analysis**: Mixed-effects models for repeated measures
3. **Genetic Association**: Case-control association testing
4. **Biomarker Analysis**: ROC curves for diagnostic accuracy

### Subgroup Analyses
- **Age Groups**: 9-12 years vs. 13-16 years
- **Severity Groups**: Mild (10-20°) vs. Moderate (21-40°)
- **Progression Groups**: Stable vs. Progressive curves

## Safety Monitoring

### Adverse Events
- **Definition**: Any untoward medical occurrence
- **Reporting**: Within 24 hours of occurrence
- **Severity**: Mild, moderate, severe, life-threatening
- **Causality**: Related, possibly related, unrelated

### Data Safety Monitoring Board
- **Composition**: Independent experts in radiology, orthopedics, biostatistics
- **Meetings**: Every 6 months
- **Responsibilities**: Safety review, efficacy monitoring, protocol modifications

## Regulatory Considerations

### IRB Approval
- **Initial Approval**: Required before study initiation
- **Continuing Review**: Annual renewal required
- **Amendments**: Required for protocol modifications

### Informed Consent
- **Parental Consent**: Required for participants <18 years
- **Assent**: Required for participants ≥12 years
- **Language**: Age-appropriate, clear language
- **Translation**: Available in multiple languages

### Data Sharing
- **De-identification**: Complete removal of PHI
- **Sharing Agreements**: Formal data use agreements
- **Publication**: Results will be published in peer-reviewed journals

## Budget and Resources

### Personnel Costs
- **Principal Investigator**: 10% effort
- **Co-Investigators**: 5% effort each
- **Research Coordinators**: 100% effort
- **Data Manager**: 50% effort
- **Statistician**: 25% effort

### Equipment and Supplies
- **MRI Time**: $500 per scan
- **Laboratory Supplies**: $50 per participant
- **Genetic Testing**: $200 per participant
- **Data Management**: $10,000 annually

### Total Estimated Budget: $750,000 over 42 months

## Timeline and Milestones

### Phase 1: Setup (Months 1-6)
- IRB approval
- Site preparation
- Staff training
- Protocol finalization

### Phase 2: Recruitment (Months 7-30)
- Participant recruitment
- Baseline assessments
- Data collection initiation

### Phase 3: Follow-up (Months 13-42)
- Follow-up assessments
- Data collection completion
- Preliminary analysis

### Phase 4: Analysis and Reporting (Months 37-42)
- Statistical analysis
- Manuscript preparation
- Results dissemination

## Expected Outcomes

### Primary Outcome
- Significant difference in CSF flow velocity between IS patients and controls
- Correlation between CSF flow abnormalities and curve progression

### Secondary Outcomes
- Identification of genetic variants associated with IS
- Validation of nasal cilia function as biomarker
- Establishment of normative CSF flow parameters

### Clinical Impact
- Improved understanding of IS pathophysiology
- Development of novel diagnostic biomarkers
- Potential therapeutic targets for IS prevention

This protocol provides a comprehensive framework for evaluating the motile cilia-CSF flow hypothesis in idiopathic scoliosis, with detailed procedures for all study components and rigorous quality control measures.

